Positive Results From Moderate-To-Severe Ulcerative Colitis

An investigational drug now under Food and Drug Administration review about the remedy for rheumatoid arthritis has shown positive outcomes in affected people along with moderate-to-severe ulcerative colitis, according to researchers with the University of California San Diego, School of Medicine.

Achievements from the phase 2 assessments confirmed the drug Tofacitinib achieved medical response and reduction in certain affected people affected by ulcerative colitis - a chronic inflammatory disease of one's colon were affected people experience painful sequences of rectal bleeding and diarrhea mixed with the urgent need using the restroom.

"Ulcerative colitis causes severe bouts of illness that adversely influence a person's standard living at home and work." said William Sandborn, MD, principal of the Division of Gastroenterology at the UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health System. "Oral therapy with Tofacitinib brought about good results and remission in certain affected people."

"Individuals by having more advanced case of ulcerative colitis require a potent and highly rated session," said Sandborn. "The consequences our study show Tofacitinib may insure the new approach to attacking this disease."

"The aim of this survey would be to prove that the oral inhibitor is effective in curing ulcerative colitis. The following phase of studies goal to verify the efficacy and safety traits of one's drug, will check the long run or preservation result of Tofacitinib and make sure the consequences this study," said Sandborn.